Predictive Factors of Radioactive Iodine Therapy Refractoriness in Patients with Differentiated Thyroid Carcinoma
World Journal of Nuclear Medicine · 01.09.2024 · 23 (03) · 185-190
DOI: 10.1055/s-0044-1787731 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Nuclear Medicine, erschienen am 01.09.2024. Verfasst von Majdouline Bel Lakhdar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Academic Hospital Ibn Sina, Faculty of Medicine and Pharmacy, University Mohammed V, Souissi, Rabat, Morocco. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aim
Differentiated thyroid carcinoma (DTC) is the most prevalent endocrine malignancy, with radioactive iodine (RAI) therapy being a standard of care. However, RAI refractoriness, occurring in a subset of patients, significantly impacts survival rates. Understanding predictive factors for RAI refractoriness is crucial for optimizing patient management.
Methods
This retrospective study analyzed data from 90 DTC patients at Ibn Sina University Hospital, Morocco. Patients were categorized into RAI-refractory (RAIR) and non-RAIR groups based on established criteria. Statistical analyses, including univariate and multivariate logistic regression, were performed to identify predictive factors of RAI refractoriness.
Results
Age at the time of diagnosis ≥ 54 years, primary tumor diameter ≥ 29 mm, and distal/nodal metastasis were independent predictors of RAIR-DTC. Additionally, the oncocytic carcinoma histological subtype significantly increased the risk of refractoriness. These findings were consistent with previous studies and underscored the importance of early detection and risk stratification.
Conclusion
Recognition of predictive factors for RAI refractoriness, including age, tumor size, distal/nodal metastasis, and histological subtype, facilitates early identification of high-risk patients. This enables timely intervention and personalized treatment strategies, particularly relevant in resource-limited settings. Further prospective studies are warranted to validate these findings and explore additional molecular markers for improved prediction of RAI refractoriness.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Academic Hospital Ibn Sina, Faculty of Medicine and Pharmacy, University Mohammed V, Souissi, Rabat, Morocco.
ORCID-Profile: Majdouline Bel Lakhdar, Ayat Mouaden
Zitieren
APA
Bel Lakhdar, M., Mouaden, A., Zekri, M., Alami, D., Zarouf, H., Ghfir, I., & Guerrouj, H. (2024). Predictive Factors of Radioactive Iodine Therapy Refractoriness in Patients with Differentiated Thyroid Carcinoma. World Journal of Nuclear Medicine, 23(03), 185-190. https://doi.org/10.1055/s-0044-1787731
Vancouver
Bel Lakhdar M, Mouaden A, Zekri M, Alami D, Zarouf H, Ghfir I, et al. Predictive Factors of Radioactive Iodine Therapy Refractoriness in Patients with Differentiated Thyroid Carcinoma. World Journal of Nuclear Medicine. 2024;23(03):185-190. doi:10.1055/s-0044-1787731
BibTeX
@article{BelLakhdar2024,
author = {Bel Lakhdar, Majdouline and Mouaden, Ayat and Zekri, Mourad and Alami, Dounia and Zarouf, Hamza and Ghfir, Imad and Guerrouj, Hasnae},
title = {Predictive Factors of Radioactive Iodine Therapy Refractoriness in Patients with Differentiated Thyroid Carcinoma},
journal = {World Journal of Nuclear Medicine},
year = {2024},
volume = {23},
number = {03},
pages = {185--190},
doi = {10.1055/s-0044-1787731}
}
EUVIMED